Explore
Validate
LearnA00457-2
antibody from Boster Biological Technology
Targeting: ABCG2
ABCP, BCRP, CD338, EST157481, MXR
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- A00457-2 - Provider product page
- Provider
- Boster Biological Technology
- Product name
- Anti-BCRP/ABCG2 Antibody Picoband™
- Antibody type
- Polyclonal
- Description
- Rabbit IgG polyclonal antibody for BCRP/ABCG2 detection. Tested with WB, IHC-P, FCM, Direct ELISA in Human;Mouse;Rat.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Vial size
- 100μg/vial
- Concentration
- Add 0.2ml of distilled water will yield a concentration of 500ug/ml.
- Storage
- At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquoted and stored frozen at -20°C for a longer time. Avoid repeated freezing and thawing.
- Handling
- Add 0.2ml of distilled water will yield a concentration of 500ug/ml.
Submitted references Herb-drug interactions: Quantitative analysis of levofloxacin absorption and transporter expression in the rat intestine following combined treatment with Persicaria capitata (Buch.-Ham. ex D. Don) H. Gross.
Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer.
Tea (Camellia sinensis) Ameliorates Hyperuricemia via Uric Acid Metabolic Pathways and Gut Microbiota.
β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Disclosure of a stem cell phenotype in an oral squamous cell carcinoma cell line induced by BMP-4 via an epithelial-mesenchymal transition.
Zhou Y, Chi M, Zhou Z, Wang L, Yuan L, Zheng L, Huang Y
Journal of pharmaceutical and biomedical analysis 2024 Aug 1;245:116156
Journal of pharmaceutical and biomedical analysis 2024 Aug 1;245:116156
Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer.
Liu K, Chen Y, Shi XB, Xing ZH, He ZJ, Wang ST, Li YC, Liu WJ, Zhang PW, Yu ZZ, Mo XM, Shi XY, Chen ZS, Shi Z
Recent patents on anti-cancer drug discovery 2022;17(4):387-395
Recent patents on anti-cancer drug discovery 2022;17(4):387-395
Tea (Camellia sinensis) Ameliorates Hyperuricemia via Uric Acid Metabolic Pathways and Gut Microbiota.
Wu D, Chen R, Li Q, Lai X, Sun L, Zhang Z, Wen S, Sun S, Cao F
Nutrients 2022 Jun 27;14(13)
Nutrients 2022 Jun 27;14(13)
β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Zhu TZ, Li XM, Luo LH, Song ZQ, Gao X, Li ZQ, Su JY, Liang GB
International journal of oncology 2014 Aug;45(2):699-709
International journal of oncology 2014 Aug;45(2):699-709
Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN, Zhao LJ, Wu LN, He MF, Qu JW, Zhao YB, Zhao WZ, Li JS, Wang JH
Asian Pacific journal of cancer prevention : APJCP 2013;14(9):4983-8
Asian Pacific journal of cancer prevention : APJCP 2013;14(9):4983-8
Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J, Mansour HM, Zhang Y, Deng X, Chen Y, Wang J, Pan Y, Zhao J
International journal of pharmaceutics 2012 Apr 15;426(1-2):193-201
International journal of pharmaceutics 2012 Apr 15;426(1-2):193-201
Disclosure of a stem cell phenotype in an oral squamous cell carcinoma cell line induced by BMP-4 via an epithelial-mesenchymal transition.
Qiao B, Johnson NW, Chen X, Li R, Tao Q, Gao J
Oncology reports 2011 Aug;26(2):455-61
Oncology reports 2011 Aug;26(2):455-61
No comments: Submit comment
Supportive validation
- Submitted by
- Boster Biological Technology (provider)
- Main image
- Experimental details
- Western blot analysis of BCRP/ABCG2 using anti-BCRP/ABCG2 antibody (A00457-2). Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 50ug of sample under reducing conditions. Lane 1: human A549 whole cell lysates, Lane 2: human MDA-MB-453 whole cell lysates, Lane 3: human HepG2 whole cell lysates, Lane 4: human Caco-2 whole cell lysates, Lane 5: human PC-3 whole cell lysates, Lane 6: rat liver tissue lysates, Lane 7: rat kidney tissue lysates, Lane 8: mouse HEPA1-6 whole cell lysates. After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-BCRP/ABCG2 antigen affinity purified polyclonal antibody (Catalog # A00457-2) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for BCRP/ABCG2 at approximately 65-80KD. The expected band size for BCRP/ABCG2 is at 72KD.
- Additional image
